PRESS RELEASES
SANOFI AT A GLANCE

Press releases

March 30, 2023
Press releases
Press Release: Availability of the Q1 2023 Memorandum for modelling purposes
March 23, 2023
Press releases
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial 
March 21, 2023
Press releases
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 
March 18, 2023
Press releases
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
March 16, 2023
Press releases
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
ALL PRESS RELEASES

Contact the Media team

Global Media Relations Department
54 rue La Boétie
75008 Paris FRANCE

ALL THE CONTACTS

You are a journalist and have a question about Sanofi, please contact the Global Media Relations team: please note the contact details are only for Medias. For any other request, please call the switchboard: +33 1 53 77 40 00

Email Alerts

Resources

Sanofi at a glance

Publications

Our Integrated Report 2021

Annual Report on Form 20-F 2021

Half Year 2022 Financial Report

ALL THE PUBLICATIONS

Press Statements

Find out more about all our press statements